Wealthfront Advisers LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

Wealthfront Advisers LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,006 shares of the biopharmaceutical company’s stock, valued at approximately $4,369,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $826.64 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a market capitalization of $85.11 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.43 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $844.92. The company has a 50 day moving average price of $692.65 and a 200 day moving average price of $715.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 over the last 90 days. Company insiders own 6.97% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes abnormal bone formation. Approval was supported by Phase 3 OPTIMA data showing a 90% or greater reduction in new heterotopic-ossification lesions at 56 weeks, along with fewer clinician-assessed flare-ups. Pasatru is described as the first and only FDA-approved treatment demonstrating these benefits, adding a specialized rare-disease product to Regeneron’s commercial portfolio. Reuters FDA approval article
• Positive Sentiment: The approval creates a potential new revenue stream and strengthens Regeneron’s focus on high-complexity immunology and rare diseases. However, FOP’s very small patient population limits the drug’s absolute market opportunity, while competition from Ipsen could affect adoption and sales. BioPharma Dive Pasatru article
• Neutral Sentiment: Regeneron also reported an update to its Phase 2 study of olatorepatide, signaling continued efforts to enter the obesity-treatment market. The trial remains mid-stage, so any commercial benefit is still several steps away and dependent on future efficacy and safety results. TipRanks olatorepatide article
• Neutral Sentiment: Leerink Partners raised its price target to $824, indicating limited near-term upside relative to the trading level and suggesting the FDA approval may already be substantially reflected in the valuation. Leerink Partners price-target article
• Negative Sentiment: Multiple law firms publicized a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to disclosures surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol amendment and concerns that previously positive messaging did not adequately reflect statistical and trial risks. The notices are largely duplicative, but they reinforce legal, reputational and pipeline uncertainty for REGN. Regeneron securities class-action notice

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Canaccord Genuity Group dropped their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Citigroup boosted their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Finally, BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $801.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.